Stockscreener 앱 받기
47.80
0.79%
-0.38
시간 외 거래:
49.40
1.60
+3.35%
전일 마감가:
$48.18
열려 있는:
$48.17
하루 거래량:
1.78M
Relative Volume:
1.78
시가총액:
$3.81B
수익:
$541.74M
순이익/손실:
$88.01M
주가수익비율:
44.01
EPS:
1.0862
순현금흐름:
$155.34M
1주 성능:
+8.12%
1개월 성능:
+44.45%
6개월 성능:
+3.55%
1년 성능:
+78.76%
1일 변동 폭
$46.36
$48.17
1주일 범위
$43.05
$49.25
52주 변동 폭
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
47.80 | 3.84B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
VCYT Maintained by Needham -- Price Target Raised to $57.00 - GuruFocus
Needham raises Veracyte stock price target to $57 on trial data By Investing.com - Investing.com South Africa
Veracyte (VCYT) Launches Prosigna Breast Risk Test for Cancer Pr - GuruFocus
Needham raises Veracyte stock price target to $57 on trial data - Investing.com UK
Veracyte Inc Investor Call on ASCO Findings Transcript - GuruFocus
Veracyte launches Prosigna breast cancer test in U.S. By Investing.com - Investing.com Nigeria
Veracyte launches Prosigna breast cancer test in U.S. - Investing.com
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. - Business Wire
Veracyte Inc stock (US92347M1009): Nasdaq diagnostics name steadies after recent gains - AD HOC NEWS
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer - BioSpace
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - BioSpace
Veracyte (VCYT) Unveils Promising Findings from Enzamet Trial - GuruFocus
Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer - TradingView
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Ve - The National Law Review
A Look at Veracyte Inc (VCYT) After 7.8% Gain -- GF Value $37.84 vs Price $47.99 - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform (NASDAQ:VCYT) - Seeking Alpha
Veracyte chief accounting officer sells $1.09m in stock By Investing.com - Investing.com Nigeria
Veracyte chief accounting officer sells $1.09m in stock - Investing.com
Veracyte (VCYT) CAO exercises options and sells 24,000 shares in Form 4 filing - Stock Titan
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now? - Yahoo Finance
Veracyte genomic test identifies breast cancer patients who can skip chemo - whbl.com
How Veracyte Inc. (VCYT) Affects Rotational Strategy Timing - Stock Traders Daily
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
How Investors Are Reacting To Veracyte (VCYT) ASCO Phase III Data And New Oncology Launch Plans - Sahm
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo - TradingView
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally? - Yahoo Finance Singapore
Here's Why Veracyte (VCYT) is a Strong Momentum Stock - Yahoo Finance
Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests - Yahoo Finance
Veracyte director Robert S Epstein sells $440,129 in company stock By Investing.com - Investing.com India
Insider Sell: Robert Epstein Sells 10,000 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte director Robert S Epstein sells $440,129 in company stock - Investing.com UK
Veracyte Insider Sold Shares Worth $440,129, According to a Recent SEC Filing - Moomoo
Veracyte (VCYT) director sells 10,000-share block under 10b5-1 plan - Stock Titan
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
New cancer test data at ASCO aim to spare patients chemotherapy - Stock Titan
Kevin Haas Named Chief Development and Technology Officer at Veracyte - Medical Product Outsourcing
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
Veracyte Jumps 7.8% Amid Sector-Wide Rally - AlphaStreet
[144] VERACYTE, INC. SEC Filing - Stock Titan
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veracyte Inc 주식 (VCYT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wygant Jonathan | VP, Chief Accounting Officer |
May 22 '26 |
Sale |
45.40 |
24,000 |
1,089,624 |
45,434 |
| EPSTEIN ROBERT S | Director |
May 20 '26 |
Sale |
44.01 |
10,000 |
440,129 |
52,446 |
0.50%
1.15%
자본화:
|
볼륨(24시간):